Innate Pharma SA entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
 
Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies.

Innate will receive a $5 million upfront payment and is eligible to receive up to $410 million in potential future development, regulatory and commercial milestones, plus royalties on potential net sales of any commercial product resulting from the license.

Yannis Morel, executive vice president, product portfolio strategy & business development at Innate Pharma said: “We are thrilled to be working with Takeda, a company which has been very successful in developing new drugs across multiple therapeutic areas. This agreement expands the application of Innate’s science beyond our oncology focus and demonstrates how our antibody engineering expertise can play a major role in developing Antibody Drug Conjugate formats. Our antibody platform has the broad ability to contribute to modalities not only via NK Cell Engagers through our ANKET technology but also with Antibody Drug Conjugates.”